Annual EBITDA
-$468.58 M
-$136.59 M-41.14%
31 December 2023
Summary:
Cytokinetics Incorporated annual earnings before interest, taxes, depreciation & amortization is currently -$468.58 million, with the most recent change of -$136.59 million (-41.14%) on 31 December 2023. During the last 3 years, it has fallen by -$381.79 million (-439.94%). CYTK annual EBITDA is now -1827.53% below its all-time high of $27.12 million, reached on 31 December 2009.CYTK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$135.84 M
-$19.22 M-16.48%
30 September 2024
Summary:
Cytokinetics Incorporated quarterly earnings before interest, taxes, depreciation & amortization is currently -$135.84 million, with the most recent change of -$19.22 million (-16.48%) on 30 September 2024. Over the past year, it has dropped by -$22.26 million (-19.60%). CYTK quarterly EBITDA is now -340.07% below its all-time high of $56.58 million, reached on 30 June 2009.CYTK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$481.94 M
-$22.26 M-4.84%
30 September 2024
Summary:
Cytokinetics Incorporated TTM earnings before interest, taxes, depreciation & amortization is currently -$481.94 million, with the most recent change of -$22.26 million (-4.84%) on 30 September 2024. Over the past year, it has dropped by -$19.30 million (-4.17%). CYTK TTM EBITDA is now -1759.39% below its all-time high of $29.04 million, reached on 30 September 2009.CYTK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CYTK EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -41.1% | -19.6% | -4.2% |
| 3 y3 years | -439.9% | -98.3% | -145.9% |
| 5 y5 years | -461.3% | -501.8% | -426.1% |
CYTK EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -439.9% | at low | -1478.9% | at low | -171.9% | at low |
| 5 y | 5 years | -461.3% | at low | -2098.2% | at low | -541.2% | at low |
| alltime | all time | -1827.5% | at low | -340.1% | at low | -1759.4% | at low |
Cytokinetics Incorporated EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$135.84 M(+16.5%) | -$481.94 M(+4.8%) |
| June 2024 | - | -$116.61 M(+0.5%) | -$459.67 M(+0.7%) |
| Mar 2024 | - | -$115.99 M(+2.2%) | -$456.48 M(-0.0%) |
| Dec 2023 | -$468.58 M(+41.1%) | -$113.50 M(-0.1%) | -$456.68 M(-1.3%) |
| Sept 2023 | - | -$113.57 M(+0.1%) | -$462.64 M(-2.4%) |
| June 2023 | - | -$113.42 M(-2.4%) | -$474.20 M(+28.4%) |
| Mar 2023 | - | -$116.20 M(-2.7%) | -$369.39 M(+11.3%) |
| Dec 2022 | -$331.99 M(+80.7%) | -$119.45 M(-4.5%) | -$331.99 M(+41.9%) |
| Sept 2022 | - | -$125.14 M(+1354.6%) | -$233.88 M(+31.9%) |
| June 2022 | - | -$8.60 M(-89.1%) | -$177.25 M(-20.4%) |
| Mar 2022 | - | -$78.79 M(+269.1%) | -$222.72 M(+21.2%) |
| Dec 2021 | -$183.71 M(+111.7%) | -$21.35 M(-68.8%) | -$183.71 M(-6.3%) |
| Sept 2021 | - | -$68.51 M(+26.7%) | -$195.97 M(+62.4%) |
| June 2021 | - | -$54.07 M(+35.9%) | -$120.66 M(+24.2%) |
| Mar 2021 | - | -$39.78 M(+18.4%) | -$97.15 M(+11.9%) |
| Dec 2020 | -$86.78 M(-6.7%) | -$33.61 M(-594.4%) | -$86.78 M(+15.5%) |
| Sept 2020 | - | $6.80 M(-122.2%) | -$75.16 M(-28.1%) |
| June 2020 | - | -$30.56 M(+3.9%) | -$104.53 M(+5.2%) |
| Mar 2020 | - | -$29.41 M(+33.8%) | -$99.36 M(+6.8%) |
| Dec 2019 | -$93.04 M(+11.4%) | -$21.98 M(-2.6%) | -$93.04 M(+1.6%) |
| Sept 2019 | - | -$22.57 M(-11.1%) | -$91.61 M(+7.3%) |
| June 2019 | - | -$25.39 M(+10.0%) | -$85.36 M(+4.6%) |
| Mar 2019 | - | -$23.09 M(+12.3%) | -$81.64 M(-1.8%) |
| Dec 2018 | -$83.49 M(-23.3%) | -$20.56 M(+25.9%) | -$83.17 M(-14.9%) |
| Sept 2018 | - | -$16.32 M(-24.7%) | -$97.75 M(-10.0%) |
| June 2018 | - | -$21.67 M(-12.0%) | -$108.62 M(-2.2%) |
| Mar 2018 | - | -$24.62 M(-30.0%) | -$111.10 M(+2.0%) |
| Dec 2017 | -$108.87 M(-647.3%) | -$35.14 M(+29.2%) | -$108.88 M(+65.9%) |
| Sept 2017 | - | -$27.20 M(+12.6%) | -$65.64 M(+1466.5%) |
| June 2017 | - | -$24.14 M(+7.8%) | -$4.19 M(-145.4%) |
| Mar 2017 | - | -$22.39 M(-376.7%) | $9.22 M(-53.7%) |
| Dec 2016 | $19.89 M(-154.3%) | $8.09 M(-76.4%) | $19.89 M(+565.9%) |
| Sept 2016 | - | $34.25 M(-419.1%) | $2.99 M(-107.5%) |
| June 2016 | - | -$10.73 M(-8.4%) | -$39.97 M(+0.7%) |
| Mar 2016 | - | -$11.72 M(+33.1%) | -$39.68 M(+8.1%) |
| Dec 2015 | -$36.64 M(+158.9%) | -$8.81 M(+1.2%) | -$36.72 M(+90.8%) |
| Sept 2015 | - | -$8.70 M(-16.7%) | -$19.24 M(+17.2%) |
| June 2015 | - | -$10.44 M(+19.1%) | -$16.41 M(+15.1%) |
| Mar 2015 | - | -$8.76 M(-201.1%) | -$14.26 M(+0.7%) |
| Dec 2014 | -$14.16 M(-57.5%) | $8.67 M(-247.6%) | -$14.16 M(-12.2%) |
| Sept 2014 | - | -$5.87 M(-29.1%) | -$16.13 M(-29.2%) |
| June 2014 | - | -$8.29 M(-4.4%) | -$22.76 M(-22.6%) |
| Mar 2014 | - | -$8.66 M(-229.4%) | -$29.43 M(-11.6%) |
| Dec 2013 | -$33.28 M | $6.70 M(-153.5%) | -$33.28 M(-35.1%) |
| Sept 2013 | - | -$12.51 M(-16.3%) | -$51.31 M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$14.95 M(+19.4%) | -$48.70 M(+14.4%) |
| Mar 2013 | - | -$12.52 M(+10.6%) | -$42.58 M(+7.0%) |
| Dec 2012 | -$39.78 M(-14.5%) | -$11.33 M(+14.4%) | -$39.80 M(-0.8%) |
| Sept 2012 | - | -$9.90 M(+12.2%) | -$40.12 M(-1.2%) |
| June 2012 | - | -$8.82 M(-9.5%) | -$40.59 M(-9.8%) |
| Mar 2012 | - | -$9.75 M(-16.3%) | -$45.00 M(-3.3%) |
| Dec 2011 | -$46.52 M(-1.8%) | -$11.64 M(+12.2%) | -$46.52 M(+1.1%) |
| Sept 2011 | - | -$10.38 M(-21.6%) | -$46.01 M(-3.5%) |
| June 2011 | - | -$13.23 M(+17.3%) | -$47.66 M(+1.3%) |
| Mar 2011 | - | -$11.27 M(+1.3%) | -$47.04 M(-0.8%) |
| Dec 2010 | -$47.40 M(-274.8%) | -$11.13 M(-7.5%) | -$47.40 M(-1.4%) |
| Sept 2010 | - | -$12.03 M(-4.5%) | -$48.06 M(+10.2%) |
| June 2010 | - | -$12.61 M(+8.4%) | -$43.63 M(-270.7%) |
| Mar 2010 | - | -$11.63 M(-1.4%) | $25.56 M(-5.8%) |
| Dec 2009 | $27.12 M(-150.8%) | -$11.79 M(+55.3%) | $27.12 M(-6.6%) |
| Sept 2009 | - | -$7.59 M(-113.4%) | $29.04 M(+26.1%) |
| June 2009 | - | $56.58 M(-661.9%) | $23.04 M(-147.1%) |
| Mar 2009 | - | -$10.07 M(+2.0%) | -$48.95 M(-8.4%) |
| Dec 2008 | -$53.43 M(-0.4%) | -$9.87 M(-27.4%) | -$53.43 M(-7.7%) |
| Sept 2008 | - | -$13.60 M(-11.7%) | -$57.85 M(+1.9%) |
| June 2008 | - | -$15.40 M(+5.8%) | -$56.78 M(+2.9%) |
| Mar 2008 | - | -$14.55 M(+1.8%) | -$55.20 M(+2.9%) |
| Dec 2007 | -$53.66 M(-8.1%) | -$14.30 M(+14.1%) | -$53.66 M(-3.6%) |
| Sept 2007 | - | -$12.53 M(-9.3%) | -$55.63 M(-4.7%) |
| June 2007 | - | -$13.82 M(+6.2%) | -$58.38 M(-0.6%) |
| Mar 2007 | - | -$13.01 M(-20.1%) | -$58.70 M(+0.5%) |
| Dec 2006 | -$58.41 M(+40.5%) | -$16.27 M(+6.5%) | -$58.41 M(+10.0%) |
| Sept 2006 | - | -$15.28 M(+8.0%) | -$53.09 M(+11.1%) |
| June 2006 | - | -$14.14 M(+11.2%) | -$47.78 M(+8.7%) |
| Mar 2006 | - | -$12.72 M(+16.1%) | -$43.97 M(+5.8%) |
| Dec 2005 | -$41.57 M(+18.2%) | -$10.95 M(+9.9%) | -$41.57 M(-1.2%) |
| Sept 2005 | - | -$9.97 M(-3.5%) | -$42.09 M(+0.3%) |
| June 2005 | - | -$10.33 M(+0.1%) | -$41.95 M(+4.0%) |
| Mar 2005 | - | -$10.32 M(-10.1%) | -$40.33 M(+14.7%) |
| Dec 2004 | -$35.16 M(+19.5%) | -$11.47 M(+16.7%) | -$35.16 M(-45.2%) |
| Sept 2004 | - | -$9.83 M(+12.9%) | -$64.21 M(+24.1%) |
| June 2004 | - | -$8.71 M(+69.1%) | -$51.73 M(+8.3%) |
| Mar 2004 | - | -$5.15 M(-87.3%) | -$47.76 M(+0.3%) |
| Dec 2003 | -$29.41 M(+39.2%) | -$40.52 M(-1632.6%) | -$47.62 M(+571.1%) |
| Sept 2003 | - | $2.64 M(-155.9%) | -$7.09 M(-27.1%) |
| June 2003 | - | -$4.73 M(-5.5%) | -$9.74 M(+94.5%) |
| Mar 2003 | - | -$5.01 M | -$5.01 M |
| Dec 2002 | -$21.13 M(+14.9%) | - | - |
| Dec 2001 | -$18.39 M(+33.3%) | - | - |
| Dec 2000 | -$13.79 M | - | - |
FAQ
- What is Cytokinetics Incorporated annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated annual EBITDA year-on-year change?
- What is Cytokinetics Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated quarterly EBITDA year-on-year change?
- What is Cytokinetics Incorporated TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated TTM EBITDA year-on-year change?
What is Cytokinetics Incorporated annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CYTK is -$468.58 M
What is the all time high annual EBITDA for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high annual earnings before interest, taxes, depreciation & amortization is $27.12 M
What is Cytokinetics Incorporated annual EBITDA year-on-year change?
Over the past year, CYTK annual earnings before interest, taxes, depreciation & amortization has changed by -$136.59 M (-41.14%)
What is Cytokinetics Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CYTK is -$135.84 M
What is the all time high quarterly EBITDA for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high quarterly earnings before interest, taxes, depreciation & amortization is $56.58 M
What is Cytokinetics Incorporated quarterly EBITDA year-on-year change?
Over the past year, CYTK quarterly earnings before interest, taxes, depreciation & amortization has changed by -$22.26 M (-19.60%)
What is Cytokinetics Incorporated TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CYTK is -$481.94 M
What is the all time high TTM EBITDA for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high TTM earnings before interest, taxes, depreciation & amortization is $29.04 M
What is Cytokinetics Incorporated TTM EBITDA year-on-year change?
Over the past year, CYTK TTM earnings before interest, taxes, depreciation & amortization has changed by -$19.30 M (-4.17%)